+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Enzymatic Wound Debridement Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4987027
  • Report
  • January 2022
  • Region: Global
  • 120 Pages
  • Mordor Intelligence


  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Healthpoint, Ltd
  • MediWound
  • Molnlycke Health Care AB
  • Smith & Nephew

The Enzymatic Wound Debridement market is projected to grow with a CAGR of nearly 5.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases is one of the major factors boosting growth.

According to International Diabetes Federation, roughly 463 million adults were living with diabetes in the year 2019, by 2045 this will rise to 700 million and around 374 million people are at increased risk of developing type 2 diabetes. The rising cases of diabetic people indicate the rising number of chronic wounds such as Diabetic Foot Ulcers, etc. which is augmenting the growth of the market studied. Furthermore, the growing investments in research and development programs by the government to develop the medical infrastructure in this section is boosting the market growth. However, the stringent regulatory policies is the major drawback of the market growth.

Key Market Trends

Collagenase-based Enzymatic Wound Debridement Products are Expected to Witness Rapid Growth

Collagenase-based enzymatic wound debridement products are predominantly used for healing surgical wounds. Most surgical wounds after cancer surgery are relatively large and deep, which generates exudate that needs regular supervision. Thus, the proper use of these products helps handle large wounds, which substantially reduce the risk of infection. Therefore, the rising incidence of chronic diseases is anticipated to increase the demand for enzymatic wound debridement products, thereby propelling market growth over the forecast period.

Furthermore, an increasing number of accidents, such as road accidents, burns, and trauma, across the world is also projected to propel growth. According to World Health Organization, 1.35 million people die every year as a result of road traffic crashes. Thus, rise in the number of accidents is expected to boost the growth of the segment.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, high prevalence of chronic diseases and accidents in the region, and established healthcare infrastructure. According to the American Association for the Surgery of Trauma, in 2017, around 1.2 million people died globally, accounting for deaths of around 3,242 people per day in road accidents every year. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Competitive Landscape

The Enzymatic Wound Debridement market is moderately competitive and consists of several major players. Some of the companies which are currently present in the market are B. Braun Melsungen AG, ConvaTec Inc., Smith & Nephew, Integra LifeSciences Corporation, Mölnlycke Health Care AB, Healthpoint, Ltd, MediWound.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Healthpoint, Ltd
  • MediWound
  • Molnlycke Health Care AB
  • Smith & Nephew

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Chronic Wounds
4.2.2 Increasing Number of Accidents
4.2.3 Increasing Technologically Advanced Products
4.3 Market Restraints
4.3.1 Stringent regulatory policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Type
5.1.1 Chronic Wounds
5.1.2 Acute Wounds
5.2 By Product
5.2.1 Collagenase Product
5.2.2 Papain Product
5.2.3 Others
5.3 By End-User
5.3.1 Hospitals
5.3.2 Homecare
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 ConvaTec Inc.
6.1.3 Smith & Nephew
6.1.4 Integra LifeSciences Corporation
6.1.5 Molnlycke Health Care AB
6.1.6 Healthpoint, Ltd
6.1.7 MediWound
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Smith & Nephew
  • Integra LifeSciences Corporation
  • Molnlycke Health Care AB
  • Healthpoint, Ltd
  • MediWound
Note: Product cover images may vary from those shown